Previous 10 | Next 10 |
Amarin press release ( NASDAQ: AMRN ): Q2 Non-GAAP EPS of -$0.09 misses by $0.03 . Revenue of $94.4M (-38.9% Y/Y) beats by $6.19M . This decrease was driven by a decline in volume and net selling price due to the impact of an increase in generic competition in ...
Company Received Final Positive Reimbursement Decision for VAZKEPA ® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan i...
Amarin ( NASDAQ: AMRN ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is -$0.06 and the consensus Revenue Estimate is $88.21M (-42.9% Y/Y). Over the last 2 years, AMRN has beaten EPS estimates ...
HLS Therapeutics ( OTCPK:HLTRF ) signed an agreement with Ontario, for listing and public reimbursement of heart drug Vascepa on the province's Public Prescription Drug Insurance Plan. Under the Product Listing Agreement (PLA), which was effective July 21, Vascep...
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on W...
The Strategy performed in-line with its benchmark, as contributions in the consumer discretionary and energy sectors were offset by declines in industrials and financials. While current valuations are tilted toward a recession, trends in the labor market, energy commodities and corpor...
Shares of cardiovascular drug specialist Amarin (NASDAQ: AMRN) fell by another 9.2% through the first four days of trading this week, according to data provided by S&P Global Market Intelligence . As a result, the company's stock price has now dropped by a whopping 58% so fa...
Amarin ( NASDAQ: AMRN ) on Wednesday said UK's National Institute for Health and Care Excellence (NICE) had issued its final guidance recommending the company's Vazkepa medicine for reimbursement and use across the national health service in England and Wales. Vazkepa ...
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-tre...
Amarin saw a major price drop recently. This follows the earnings miss and the suspended guidance. While the company is making every effort, the true cure is in a sell. Amarin ( AMRN ) is back in the news again, with the latest being the mineral oil bogey being raise...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...